ALGORAE PHARMACEUTICALS LIMITED — AGM Information 2021

Nov 28, 2021

==> picture [241 x 140] intentionally omitted <==

Chairman’s Presentation to Extraordinary General Meeting

Professor Bernard Tuch

29 November 2021

www.lctglobal.com

Safe Harbour Statement

==> picture [113 x 52] intentionally omitted <==

This document contains certain forward-looking statements, relating to LCT’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forwardlooking statements contained in this document as a result of new information, future events or developments or otherwise.

==> picture [113 x 52] intentionally omitted <==

==> picture [720 x 201] intentionally omitted <==

Where Proceeds of Raisings Will be Directed

LCT’s Cash Position Post Raisings

==> picture [113 x 52] intentionally omitted <==

Financial ramifications of 2Q FY2021 raisings

• LCT to receive up to up to $7.3m (before costs) from 2Q FY2021 raisings

• Proforma cash position post raisings of $7.6 million

Where this additional capital will be directed

• Ongoing development of NTCELL treatment for Parkinson’s disease

• Exploring the potential for treating other medical disorders with living cells

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | LCTglobal

==> picture [113 x 52] intentionally omitted <==

==> picture [359 x 88] intentionally omitted <==

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | LCTglobal

NTCELL – what makes this IP so unique

==> picture [113 x 52] intentionally omitted <==

==> picture [533 x 316] intentionally omitted <==

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | LCTglobal

NTCELL – Stage IIb trials have been completed

==> picture [113 x 52] intentionally omitted <==

==> picture [538 x 322] intentionally omitted <==

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | LCTglobal

NTCELL – Groundwork now being laid for Stage III trials

==> picture [113 x 52] intentionally omitted <==

==> picture [532 x 316] intentionally omitted <==

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | LCTglobal

NTCELL Stage III trials – some detail and proposed timing

==> picture [113 x 52] intentionally omitted <==

==> picture [512 x 308] intentionally omitted <==

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | LCTglobal

==> picture [113 x 52] intentionally omitted <==

==> picture [720 x 201] intentionally omitted <==

Other Research & Development Initiatives

Diabecell a potential future revenue stream

==> picture [113 x 52] intentionally omitted <==

==> picture [337 x 25] intentionally omitted <==

==> picture [508 x 215] intentionally omitted <==

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | LCTglobal

Other Opportunities

==> picture [113 x 52] intentionally omitted <==

• LCT exploring ways to improve treatment for other medical disorders

• • These endeavours may be conducted in conjunction with partners

• LCT now in discussions with another party that could potentially lead to such an arrangement.

• LCT anticipates such negotiations will become more regular…

• … aligning with LCT’s aim to be a provider of living cell therapies

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com | LCTglobal

==> picture [358 x 540] intentionally omitted <==

==> picture [228 x 132] intentionally omitted <==

BERNIE TUCH, CHAIRMAN bernietuch@lctglobal.com +61 411 461 604

www.lctglobal.com